Genomics

Dataset Information

160

Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13


ABSTRACT: The constitutively active androgen receptor (AR) splice variant 7 (AR-V7) plays an important role in the progression of castration-resistant prostate cancer (CRPC). Although biomarker studies established the role of AR-V7 in resistance to AR-targeting therapies, how AR-V7 mediates genomic functions in CRPC remains largely unknown. Using a ChIP-exo approach, we show AR-V7 binds to distinct genomic regions and recognizes a full-length androgen-responsive element in CRPC cells and patient tissues. Remarkably, we find dramatic differences in AR-V7 cistromes across diverse CRPC cells and patient tissues, regulating different target gene sets involved in CRPC progression. Surprisingly, we discover that HoxB13 is universally required for and colocalizes with AR-V7 binding to open chromatin across CRPC genomes. HoxB13 pioneers AR-V7 binding through direct physical interaction, and collaborates with AR-V7 to up-regulate target oncogenes. Transcriptional coregulation by HoxB13 and AR-V7 was further supported by their coexpression in tumors and circulating tumor cells from CRPC patients. Importantly, HoxB13 silencing significantly decreases CRPC growth through inhibition of AR-V7 oncogenic function. These results identify HoxB13 as a pivotal upstream regulator of AR-V7-driven transcriptomes that are often cell context-dependent in CRPC, suggesting that HoxB13 may serve as a therapeutic target for AR-V7-driven prostate tumors. Overall design: To identify AR-V7 and HoxB13 binding sites in CRPC, ChIP-exo and ATAC-seq were performed in CRPC cells and tissues. RNA-seq was performed to examine AR-V7 and HoxB13 regulated profiles. Each experiment includes two biological replicates.

INSTRUMENT(S): Illumina HiSeq 2000 (Homo sapiens)

SUBMITTER: Zhong Chen  

PROVIDER: GSE99378 | GEO | 2018-05-31

REPOSITORIES: GEO

altmetric image

Publications


The constitutively active androgen receptor (AR) splice variant 7 (AR-V7) plays an important role in the progression of castration-resistant prostate cancer (CRPC). Although biomarker studies established the role of AR-V7 in resistance to AR-targeting therapies, how AR-V7 mediates genomic functions in CRPC remains largely unknown. Using a ChIP-exo approach, we show AR-V7 binds to distinct genomic regions and recognizes a full-length androgen-responsive element in CRPC cells and patient tissues.  ...[more]

Similar Datasets

2012-03-17 | E-GEOD-36549 | ArrayExpress
2015-04-03 | E-GEOD-67537 | ArrayExpress
| GSE43785 | GEO
2015-01-01 | E-GEOD-43678 | ArrayExpress
2018-10-05 | GSE120004 | GEO
2012-10-02 | E-GEOD-40050 | ArrayExpress
| GSE79689 | GEO
| GSE51063 | GEO
| GSE72714 | GEO
2018-10-05 | GSE120005 | GEO